Note: Ingredients listed on restricted chemical lists
General Information
Version
2.0
Revision date
2022-01-01
Product name
Potassium Iodide
CAS No.
7681-11-0
1.2.1 Relevant identified uses
i
Emergency telephone
+91-7046456789
Icons in SDS
Company Information
company name
Samrat Pharmachem Limited
e-mail address of the competent person responsible for the Safety Data Sheet
contact@samratpharmachem.in
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H302, H315, H319, H401
Hazard statements
Code
Statements
H302
Harmful if swallowed
Section 2
SECTION 2: Hazards identification
Classification of substance
2.2 Label elements
i Pictogram ii Signal word : Warning iii Hazard Statement(s) H302 : Harmful if swallowed H315 : Causes skin irritation H319 : Causes serious eye irritation H401 : Toxic to aquatic life
Precautionary statements
P264 : Wash skin thoroughly after handling P270 : Do not eat, drink or smoke when using this product. P280 : Wear protective gloves/ eye protection/ face protection. P301 + P312 : IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell. P302 + P352 : IF ON SKIN: Wash with plenty of soap and water. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P321 : Specific treatment (see supplemental first aid instructions on the label). P330 : Rinse mouth. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P362 : Take off contaminated clothing and wash before reuse. P501 : Dispose of contents/ container to an approved waste disposal plant.
2.3 Other hazards
NFPA Scale (0-4) HMIS Rating (0-4)
2.1 Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) i H302 : Acute toxicity, Oral (Category 4) ii H315 : Skin irritation (Category 2) iii H319 : Eye irritation (Category 2A) For full text of H-statements mentioned in this section, see section 16